Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11883194rdf:typepubmed:Citationlld:pubmed
pubmed-article:11883194lifeskim:mentionsumls-concept:C0042760lld:lifeskim
pubmed-article:11883194lifeskim:mentionsumls-concept:C1883540lld:lifeskim
pubmed-article:11883194lifeskim:mentionsumls-concept:C1709694lld:lifeskim
pubmed-article:11883194lifeskim:mentionsumls-concept:C1709915lld:lifeskim
pubmed-article:11883194lifeskim:mentionsumls-concept:C1511545lld:lifeskim
pubmed-article:11883194lifeskim:mentionsumls-concept:C0121925lld:lifeskim
pubmed-article:11883194pubmed:issue2lld:pubmed
pubmed-article:11883194pubmed:dateCreated2002-3-8lld:pubmed
pubmed-article:11883194pubmed:abstractTextThe biological form of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) is a heterodimer consisting of two polypeptides, p66 and p51, which have identical N-termini. The p51 polypeptide is generated by action of viral protease cleaving the p66 polypeptide between residues Phe440 and Tyr441. Dimerization has been mostly studied using bacterially purified RT bearing amino acid changes in either subunit, but not in the context of HIV-1 particles. We introduced changes of conserved amino acid residues 430-438 into the protease-sensitive subdomain of the p66 subunit and analyzed the reverse transcriptase processing and function using purified variants and their corresponding HIV-1 recombinant clones. Our mutational analysis shows that the conserved Glu438 residue is critical for proper heterodimerization and function of virion-associated RT, but not of bacterially expressed RT. In contrast, the conserved Glu430, Glu432, and Pro433 residues are not important for dimerization of virion-associated RT. The network of interactions made by the Glu438 carboxyl group with neighboring residues is critical to protect the Phe440-Tyr441 from cleavage in the context of the p66/p51 heterodimer and may explain why the p66/p51 is not processed further to p51/p51.lld:pubmed
pubmed-article:11883194pubmed:languageenglld:pubmed
pubmed-article:11883194pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11883194pubmed:citationSubsetIMlld:pubmed
pubmed-article:11883194pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11883194pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11883194pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11883194pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11883194pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11883194pubmed:statusMEDLINElld:pubmed
pubmed-article:11883194pubmed:monthNovlld:pubmed
pubmed-article:11883194pubmed:issn0042-6822lld:pubmed
pubmed-article:11883194pubmed:authorpubmed-author:NavarroJ MJMlld:pubmed
pubmed-article:11883194pubmed:authorpubmed-author:SireJJlld:pubmed
pubmed-article:11883194pubmed:authorpubmed-author:BorettoJJlld:pubmed
pubmed-article:11883194pubmed:authorpubmed-author:CanardBBlld:pubmed
pubmed-article:11883194pubmed:authorpubmed-author:PriesPPlld:pubmed
pubmed-article:11883194pubmed:authorpubmed-author:QuératGGlld:pubmed
pubmed-article:11883194pubmed:authorpubmed-author:DamierLLlld:pubmed
pubmed-article:11883194pubmed:issnTypePrintlld:pubmed
pubmed-article:11883194pubmed:day25lld:pubmed
pubmed-article:11883194pubmed:volume290lld:pubmed
pubmed-article:11883194pubmed:ownerNLMlld:pubmed
pubmed-article:11883194pubmed:authorsCompleteYlld:pubmed
pubmed-article:11883194pubmed:pagination300-8lld:pubmed
pubmed-article:11883194pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:11883194pubmed:meshHeadingpubmed-meshheading:11883194...lld:pubmed
pubmed-article:11883194pubmed:meshHeadingpubmed-meshheading:11883194...lld:pubmed
pubmed-article:11883194pubmed:meshHeadingpubmed-meshheading:11883194...lld:pubmed
pubmed-article:11883194pubmed:meshHeadingpubmed-meshheading:11883194...lld:pubmed
pubmed-article:11883194pubmed:meshHeadingpubmed-meshheading:11883194...lld:pubmed
pubmed-article:11883194pubmed:meshHeadingpubmed-meshheading:11883194...lld:pubmed
pubmed-article:11883194pubmed:meshHeadingpubmed-meshheading:11883194...lld:pubmed
pubmed-article:11883194pubmed:meshHeadingpubmed-meshheading:11883194...lld:pubmed
pubmed-article:11883194pubmed:meshHeadingpubmed-meshheading:11883194...lld:pubmed
pubmed-article:11883194pubmed:meshHeadingpubmed-meshheading:11883194...lld:pubmed
pubmed-article:11883194pubmed:meshHeadingpubmed-meshheading:11883194...lld:pubmed
pubmed-article:11883194pubmed:meshHeadingpubmed-meshheading:11883194...lld:pubmed
pubmed-article:11883194pubmed:meshHeadingpubmed-meshheading:11883194...lld:pubmed
pubmed-article:11883194pubmed:meshHeadingpubmed-meshheading:11883194...lld:pubmed
pubmed-article:11883194pubmed:meshHeadingpubmed-meshheading:11883194...lld:pubmed
pubmed-article:11883194pubmed:meshHeadingpubmed-meshheading:11883194...lld:pubmed
pubmed-article:11883194pubmed:meshHeadingpubmed-meshheading:11883194...lld:pubmed
pubmed-article:11883194pubmed:meshHeadingpubmed-meshheading:11883194...lld:pubmed
pubmed-article:11883194pubmed:year2001lld:pubmed
pubmed-article:11883194pubmed:articleTitleGlutamic residue 438 within the protease-sensitive subdomain of HIV-1 reverse transcriptase is critical for heterodimer processing in viral particles.lld:pubmed
pubmed-article:11883194pubmed:affiliationINSERM U372, 163 avenue de Luminy, BP 178, 13276 Marseille, France.lld:pubmed
pubmed-article:11883194pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11883194pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11883194lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11883194lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11883194lld:pubmed